These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 21993674)

  • 41. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
    Das-Gupta E; Thomson KJ; Bloor AJC; Clark AD; Mackinnon S; Kayani I; Clifton-Hadley L; Patrick P; El-Mehidi N; Lawrie A; Kirkwood AA; Russell NH; Linch DC; Peggs KS
    Blood Adv; 2019 Dec; 3(24):4264-4270. PubMed ID: 31869413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 43. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Marcais A; Porcher R; Robin M; Mohty M; Michalet M; Blaise D; Tabrizi R; Clement L; Ceballos P; Daguindau E; Bilger K; Dhedin N; Lapusan S; Bay JO; Pautas C; Garban F; Ifrah N; Guillerm G; Contentin N; Bourhis JH; Yakoub Agha I; Bernard M; Cornillon J; Milpied N
    Haematologica; 2013 Sep; 98(9):1467-75. PubMed ID: 23539540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
    Dodero A; Patriarca F; Milone G; Sarina B; Miceli R; Iori A; Barretta F; Terruzzi E; Mussetti A; Pini M; Bosi A; Dominietto A; Cascavilla N; Onida F; Narni F; Farina L; Rambaldi A; Corradini P
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1102-1109. PubMed ID: 28390983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.
    Constans M; Sureda A; Terol MJ; Arranz R; Caballero MD; Iriondo A; Jarque I; Carreras E; Moraleda JM; Carrera D; León A; López A; Albó C; Díaz-Mediavilla J; Fernández-Abellán P; García-Ruiz JC; Hernández-Navarro F; Mataix R; Petit J; Pascual MJ; Rifón J; García-Conde J; Fernández-Rañada JM; Mateos MV; Sierra J; Conde E;
    Ann Oncol; 2003 May; 14(5):745-51. PubMed ID: 12702529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
    Robinson SP; Sureda A; Canals C; Russell N; Caballero D; Bacigalupo A; Iriondo A; Cook G; Pettitt A; Socie G; Bonifazi F; Bosi A; Michallet M; Liakopoulou E; Maertens J; Passweg J; Clarke F; Martino R; Schmitz N;
    Haematologica; 2009 Feb; 94(2):230-8. PubMed ID: 19066328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.
    Federmann B; Bornhauser M; Meisner C; Kordelas L; Beelen DW; Stuhler G; Stelljes M; Schwerdtfeger R; Christopeit M; Behre G; Faul C; Vogel W; Schumm M; Handgretinger R; Kanz L; Bethge WA
    Haematologica; 2012 Oct; 97(10):1523-31. PubMed ID: 22491731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning.
    Einsele H; Schäfer HJ; Hebart H; Bader P; Meisner C; Plasswilm L; Liebisch P; Bamberg M; Faul C; Kanz L
    Br J Haematol; 2003 May; 121(3):411-8. PubMed ID: 12716363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
    Sureda A; Arranz R; Iriondo A; Carreras E; Lahuerta JJ; García-Conde J; Jarque I; Caballero MD; Ferrà C; López A; García-Laraña J; Cabrera R; Carrera D; Ruiz-Romero MD; León A; Rifón J; Díaz-Mediavilla J; Mataix R; Morey M; Moraleda JM; Altés A; López-Guillermo A; de la Serna J; Fernández-Rañada JM; Sierra J; Conde E;
    J Clin Oncol; 2001 Mar; 19(5):1395-404. PubMed ID: 11230484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
    Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.